-DOCSTART-	O

Title	O
:	O
Acceleration	O
of	O
insulin	O
pharmacodynamic	O
profile	O
by	O
a	B-I
novel	I-I
insulin	I-I
infusion	I-I
site	I-I
warming	I-I
device	I-I
.	O

METHODS	O
:	O
Each	O
subject	O
underwent	O
two	O
euglycemic	O
clamp	O
procedures	O
on	O
separate	O
occasions	O
:	O
one	O
with	B-I
IP	I-I
and	O
one	O
without	B-C
IP	I-C
activation	I-C
in	O
random	O
order	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
strontium	B-I
on	O
the	O
quality	O
of	O
bone	O
apatite	O
crystals	O
:	O
a	O
paired	O
biopsy	O
study	O
in	O
postmenopausal	O
osteoporotic	O
women	O
.	O

In	O
paired	O
biopsies	O
of	O
osteoporotic	O
women	O
treated	O
with	O
either	O
strontium	O
ranelate	O
or	O
a	O
placebo	O
for	O
36	O
months	O
,	O
characteristics	O
of	O
bone	O
apatite	O
crystals	O
were	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
strontium	O
.	O

The	O
mean	O
rate	O
of	O
substitutions	O
of	O
calcium	O
by	O
strontium	O
ions	O
was	O
4	O
.	O
5	O
%	O
.	O

METHODS	O
:	O
In	O
ten	B-P
paired	I-P
biopsies	I-P
,	O
crystallinity	B-O
,	O
apparent	B-O
length	I-O
and	O
width	B-O
/	I-O
thickness	I-O
of	I-O
crystals	I-O
,	O
interplanar	B-O
distances	I-O
,	O
and	O
lattice	B-O
parameters	I-O
of	I-O
unit	I-O
cells	I-O
were	O
assessed	O
by	O
X	B-O
-	I-O
ray	I-O
diffraction	I-O
and	O
selected	B-O
area	I-O
electron	I-O
diffraction	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Social	B-I
robots	I-I
as	O
embedded	O
reinforcers	O
of	O
social	O
behavior	O
in	O
children	B-P
with	I-P
autism	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Parents	O
'	O
state	O
and	O
trait	O
anxiety	O
:	O
relationships	O
with	O
anxiety	O
severity	O
and	O
treatment	O
response	O
in	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

-DOCSTART-	O

Title	O
:	O
A	O
phase	O
III	O
study	O
of	O
laparoscopy	B-I
-	I-I
assisted	I-I
versus	O
open	B-I
distal	I-I
gastrectomy	I-I
with	I-I
nodal	I-I
dissection	I-I
for	O
clinical	O
stage	O
IA	O
/	O
IB	O
gastric	O
Cancer	O
(	O
JCOG0912	O
)	O
.	O

METHODS	O
:	O
This	O
study	O
followed	O
the	O
previous	O
Phase	O
II	O
study	O
to	O
confirm	O
the	O
safety	O
of	O
laparoscopy	B-I
-	I-I
assisted	I-I
distal	I-I
gastrectomy	I-I
(	O
JCOG0703	O
)	O
and	O
began	O
in	O
March	O
2010	O
.	O

A	B-P
total	I-P
of	I-P
920	I-P
patients	I-P
will	O
be	O
accrued	O
from	O
33	O
institutions	O
within	O
5	O
years	O
.	O

The	O
primary	O
endpoint	O
is	O
overall	B-O
survival	I-O
.	O

The	O
secondary	O
endpoints	O
are	O
relapse	B-O
-	I-O
free	I-O
survival	I-O
,	O
proportion	B-O
of	I-O
laparoscopy	I-O
-	I-O
assisted	I-O
distal	I-O
gastrectomy	I-O
completion	I-O
,	O
proportion	B-O
of	I-O
conversion	I-O
to	I-O
open	I-O
surgery	I-O
,	O
adverse	B-O
events	I-O
,	O
short	B-O
-	I-O
term	I-O
clinical	I-O
outcomes	I-O
,	O
postoperative	B-O
quality	I-O
of	I-O
life	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Antihistamines	B-I
do	O
not	O
inhibit	O
the	O
wheal	O
induced	O
by	O
the	O
intradermal	O
injection	O
of	O
autologous	O
serum	O
in	O
resistant	O
chronic	O
idiopathic	O
urticaria	O
.	O

METHODS	O
:	O
CIU	B-P
patients	I-P
with	I-P
treatment	I-P
failure	I-P
under	I-P
fexofenadine	I-P
at	I-P
180	I-P
mg	I-P
q	I-P
.	I-P
d	I-P
.	I-P
increased	O
their	O
daily	B-I
dose	I-I
of	I-I
AH	I-I
to	O
4	O
tablets	O
daily	O
.	O

Those	O
with	O
significant	O
improvement	O
of	O
urticaria	O
activity	O
score	O
under	O
fexofenadine	O
at	O
180	O
mg	O
were	O
included	O
in	O
the	O
CIU	O
group	O
.	O

Subjects	O
with	O
treatment	O
failure	O
despite	O
a	O
full	O
8	O
-	O
week	O
fourfold	O
fexofenadine	O
treatment	O
were	O
included	O
in	O
the	O
resistant	O
CIU	O
(	O
R	O
-	O
CIU	O
group	O
)	O
.	O

The	O
control	O
group	O
consisted	O
of	O
sex	O
-	O
and	O
age	O
-	O
matched	O
patents	O
with	O
allergic	O
rhinitis	O
.	O

The	B-O
AS	I-O
skin	I-O
test	I-O
and	O
intradermal	B-O
histamine	I-O
-	I-O
induced	I-O
wheal	I-O
and	O
flare	B-O
reaction	I-O
were	O
performed	O
at	O
baseline	O
(	O
without	O
AH	O
)	O
,	O
after	O
8	O
and	O
16	O
weeks	O
(	O
under	O
AH	O
treatment	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	O
body	O
mass	O
index	O
and	O
dyslipidemia	O
in	O
dialysis	B-P
patients	I-P
linked	I-P
to	I-P
elevated	I-P
plasma	I-P
fibroblast	I-P
growth	I-P
factor	I-P
23	I-P
.	O

METHODS	O
:	O
This	O
study	O
was	O
conducted	O
among	O
654	B-P
patients	I-P
receiving	I-P
chronic	I-P
hemodialysis	I-P
.	O

C	B-O
-	I-O
terminal	I-O
FGF23	I-O
concentrations	I-O
were	O
measured	O
in	O
stored	O
plasma	O
samples	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
examine	O
the	O
cross	O
-	O
sectional	O
associations	O
of	O
plasma	B-O
FGF23	I-O
concentrations	I-O
with	O
BMI	B-O
,	O
total	B-O
cholesterol	I-O
(	I-O
TC	I-O
)	I-O
,	O
low	B-O
-	I-O
density	I-O
lipoprotein	I-O
-	I-O
cholesterol	I-O
(	I-O
LDL	I-O
-	I-O
C	I-O
)	I-O
,	O
high	B-O
-	I-O
density	I-O
lipoprotein	I-O
-	I-O
cholesterol	I-O
(	I-O
HDL	I-O
-	I-O
C	I-O
)	I-O
and	O
triglycerides	B-O
.	O

Cox	O
proportional	O
hazard	O
models	O
were	O
used	O
to	O
examine	O
the	O
association	O
between	O
FGF23	B-O
concentrations	I-O
and	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Topical	O
treatment	O
of	O
tinea	O
pedis	O
using	O
6	B-I
%	I-I
coriander	I-I
oil	I-I
in	O
unguentum	O
leniens	O
:	O
a	O
randomized	O
,	O
controlled	O
,	O
comparative	O
pilot	O
study	O
.	O

METHODS	O
:	O
Half	O
-	O
side	O
comparative	O
pilot	O
study	O
on	O
subjects	O
with	O
symmetric	O
,	O
bilateral	O
interdigital	O
tinea	O
pedis	O
.	O

Active	O
drug	O
and	O
placebo	B-C
control	O
were	O
applied	O
twice	O
daily	O
on	O
the	O
affected	O
areas	O
,	O
and	O
follow	O
-	O
up	O
visits	O
were	O
performed	O
on	O
days	O
14	O
and	O
28	O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
Tiotropium	I-I
Safety	O
and	O
Performance	O
in	O
Respimat	B-I
Trial	O
(	O
TIOSPIR	O
)	O
,	O
a	O
large	O
scale	O
,	O
randomized	O
,	O
controlled	O
,	O
parallel	O
-	O
group	O
trial	O
-	O
design	O
and	O
rationale	O
.	O

METHODS	O
:	O
The	O
TIOSPIR	O
trial	O
(	O
NCT01126437	O
)	O
compares	O
the	O
safety	O
and	O
efficacy	O
of	O
tiotropium	B-I
Respimat	I-I
5	O
?g	O
once	O
daily	O
(	O
marketed	O
)	O
and	O
2	O
.	O
5	O
?g	O
once	O
daily	O
(	O
investigational	O
)	O
with	O
tiotropium	B-I
HandiHaler	I-I
18	O
?	O
once	O
daily	O
(	O
marketed	O
)	O
.	O

The	O
hypotheses	O
to	O
be	O
tested	O
are	O
1	O
)	O
.	O

that	O
tiotropium	B-I
Respimat	I-I
5	O
?g	O
once	O
daily	O
and	O
Respimat	B-I
2	O
.	O
5	O
?g	O
once	O
daily	O
are	O
non	O
-	O
inferior	O
to	O
HandiHaler	B-I
in	O
terms	O
of	O
all	O
-	O
cause	O
mortality	O
,	O
and	O
2	O
)	O
.	O

that	O
tiotropium	B-I
Respimat	I-I
5	O
?g	O
once	O
daily	O
is	O
superior	O
to	O
HandiHaler	B-I
in	O
terms	O
of	O
time	O
to	O
first	O
exacerbation	O
.	O

A	B-O
spirometry	I-O
substudy	I-O
evaluates	O
the	B-O
bronchodilator	I-O
efficacy	I-O
.	O

The	O
trial	O
is	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
double	O
dummy	O
,	O
event	O
-	O
driven	O
,	O
parallel	O
group	O
study	O
.	O

Participants	O
can	O
use	O
any	O
background	O
treatment	O
for	O
COPD	O
except	O
inhaled	O
anticholinergic	O
agents	O
.	O

The	O
study	O
encompasses	O
a	O
wide	O
range	O
of	O
COPD	B-P
patients	I-P
,	I-P
e	I-P
.	I-P
g	I-P
.	I-P
patients	I-P
with	I-P
stable	I-P
cardiac	I-P
diseases	I-P
including	I-P
arrhythmia	I-P
can	O
be	O
included	O
.	O

Clinical	O
sites	O
are	O
international	O
and	O
include	O
both	O
primary	O
care	O
as	O
well	O
as	O
specialists	O
.	O

-DOCSTART-	O

Title	O
:	O
Nasal	O
eosinophilia	O
and	O
serum	O
soluble	O
intercellular	O
adhesion	O
molecule	O
1	O
in	O
patients	B-P
with	I-P
allergic	I-P
rhinitis	I-P
treated	O
with	O
montelukast	B-I
alone	I-I
or	O
in	B-I
combination	I-I
with	I-I
desloratadine	I-I
or	O
levocetirizine	B-I
.	O

METHODS	O
:	O
In	O
this	O
single	O
-	O
center	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
,	O
two	O
-	O
arm	O
study	O
,	O
40	B-P
patients	I-P
with	I-P
persistent	I-P
AR	I-P
were	O
randomized	O
to	O
receive	O
either	O
montelukast	B-I
and	O
/	O
or	O
levocetirizine	B-I
or	O
placebo	B-C
(	O
n	O
=	O
20	O
)	O
or	O
to	O
receive	O
treatment	O
with	O
montelukast	B-I
and	O
/	O
or	O
desloratadine	B-I
or	O
placebo	B-C
(	O
n	O
=	O
20	O
)	O
.	O

Nasal	B-O
eosinophilia	I-O
and	O
concentration	B-O
of	I-O
sICAM	I-O
-	I-O
1	I-O
in	I-O
peripheral	I-O
blood	I-O
were	O
assessed	O
before	O
and	O
on	O
the	O
last	O
day	O
of	O
each	O
treatment	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	B-I
-	I-I
term	I-I
treatment	I-I
with	I-I
atomoxetine	I-I
for	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
symptoms	O
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
:	O
an	O
open	O
-	O
label	O
extension	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
88	B-P
patients	I-P
6	I-P
-	I-P
17	I-P
years	I-P
of	I-P
age	I-P
,	I-P
with	I-P
ADHD	I-P
and	I-P
ASD	I-P
,	O
were	O
treated	O
with	O
1	B-I
.	I-I
2	I-I
mg	I-I
/	I-I
kg	I-I
/	I-I
day	I-I
atomoxetine	I-I
for	O
20	O
weeks	O
as	O
follow	O
-	O
up	O
of	O
an	O
8	O
week	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
period	O
.	O

Primary	O
endpoint	O
was	O
the	B-O
ADHD	I-O
Rating	I-O
Scale	I-O
(	I-O
ADHD	I-O
-	I-O
RS	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Prevalence	O
and	O
treatment	O
outcome	O
of	O
cervicitis	O
of	O
unknown	O
etiology	O
.	O

METHODS	O
:	O
Five	B-P
hundred	I-P
seventy	I-P
-	I-P
seven	I-P
women	I-P
were	I-P
screened	I-P
for	I-P
MPC	I-P
.	O

Women	B-P
with	I-P
MPC	I-P
were	O
randomized	O
to	O
the	O
treatment	O
or	O
placebo	B-C
arm	O
of	O
the	O
study	O
,	O
and	O
the	O
2	O
arms	O
were	O
evaluated	O
based	O
on	O
the	B-O
etiology	I-O
,	O
clinical	B-O
cure	I-O
rates	I-O
,	O
adverse	B-O
events	I-O
(	I-O
AEs	I-O
)	I-O
,	O
and	O
rates	B-O
of	I-O
pelvic	I-O
inflammatory	I-O
disease	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
pharmacokinetics	O
of	O
buffered	B-I
propranolol	I-I
sublingual	I-I
tablet	I-I
(	I-I
Promptol?	I-I
)	I-I
-	O
application	O
of	O
a	O
new	O
"	O
physiologically	O
based	O
"	O
model	O
to	O
assess	O
absorption	O
and	O
disposition	O
.	O

METHODS	O
:	O
Eighteen	B-P
healthy	I-P
volunteers	I-P
received	O
10	B-I
mg	I-I
sublingual	I-I
Promptol	I-I
or	O
oral	B-I
Inderal	I-I
(	I-I
	I-I
)	I-I
.	O

Multiple	O
Cp	O
-	O
prop	O
were	O
determined	O
and	O
their	O
pharmacokinetics	O
compared	O
.	O

Additional	O
data	O
following	O
sublingual	B-I
40	I-I
mg	I-I
Promptol	I-I
or	O
Inderal	B-I
(	I-I
	I-I
)	I-I
were	O
utilized	O
for	O
evaluation	O
of	O
a	O
special	O
advanced	O
compartmental	O
absorption	O
and	O
transit	O
(	O
ACAT	O
)	O
model	O
.	O

For	O
model	O
simulation	O
,	O
the	B-O
physicochemical	I-O
parameters	I-O
were	O
imported	O
from	O
AMET	B-O
predictor	I-O
,	O
whereas	O
the	B-O
pharmacokinetic	I-O
parameters	I-O
were	O
calculated	O
and	O
optimized	O
by	O
Gastroplus	B-O
(	I-O
	I-O
)	I-O
.	O

Based	O
on	O
this	O
model	O
,	O
the	B-O
quantity	I-O
of	I-O
drug	I-O
absorbed	I-O
via	I-O
buccal	I-O
/	I-O
sublingual	I-O
mucosa	I-O
was	O
estimated	O
.	O

-DOCSTART-	O

Title	O
:	O
Health	B-I
-	I-I
education	I-I
package	I-I
to	O
prevent	O
worm	O
infections	O
in	O
Chinese	B-P
schoolchildren	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
single	O
-	O
blind	O
,	O
unmatched	O
,	O
cluster	O
-	O
randomized	O
intervention	O
trial	O
involving	O
1718	B-P
children	I-P
,	I-P
9	I-P
to	I-P
10	I-P
years	I-P
of	I-P
age	I-P
,	I-P
in	I-P
38	I-P
schools	I-P
over	I-P
the	I-P
course	I-P
of	I-P
1	I-P
school	I-P
year	I-P
.	O

Schools	O
were	O
randomly	O
assigned	O
to	O
the	B-I
health	I-I
-	I-I
education	I-I
package	I-I
,	O
which	O
included	O
a	B-I
cartoon	I-I
video	I-I
,	O
or	O
to	O
a	B-C
control	I-C
package	I-C
,	O
which	O
involved	O
only	O
the	B-C
display	I-C
of	I-C
a	I-C
health	I-C
-	I-C
education	I-C
poster	I-C
.	O

Infection	B-O
rates	I-O
,	O
knowledge	B-O
about	I-O
soil	I-O
-	I-O
transmitted	I-O
helminths	I-O
(	O
as	O
assessed	O
with	O
the	B-O
use	I-O
of	I-O
a	I-O
questionnaire	I-O
)	O
,	O
and	O
hand	B-O
-	I-O
washing	I-O
behavior	I-O
were	O
assessed	O
before	O
and	O
after	O
the	O
intervention	O
.	O

Albendazole	O
was	O
administered	O
in	O
all	O
the	O
participants	O
at	O
baseline	O
and	O
in	O
all	O
the	O
children	O
who	O
were	O
found	O
to	O
be	O
positive	O
for	O
infection	O
with	O
soil	O
-	O
transmitted	O
helminths	O
at	O
the	O
follow	O
-	O
up	O
assessment	O
at	O
the	O
end	O
of	O
the	O
school	O
year	O
.	O

-DOCSTART-	O

Title	O
:	O
Ultrasonography	B-I
-	I-I
guided	I-I
bilateral	I-I
rectus	I-I
sheath	I-I
block	I-I
vs	O
local	B-I
anesthetic	I-I
infiltration	I-I
after	O
pediatric	O
umbilical	O
hernia	O
repair	O
:	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Prospective	O
,	O
observer	O
-	O
blinded	O
,	O
randomized	O
clinical	O
trial	O
.	O

Tertiary	O
-	O
referral	O
urban	O
children	O
'	O
s	O
hospital	O
.	O

Eligible	O
children	O
3	O
to	O
12	O
years	O
of	O
age	O
undergoing	O
elective	O
umbilical	O
hernia	O
repair	O
from	O
November	O
16	O
,	O
2009	O
,	O
through	O
May	O
31	O
,	O
2011	O
.	O

Ropivacaine	B-I
hydrochloride	I-I
administered	O
at	O
the	O
conclusion	O
of	O
surgery	O
as	O
LAI	B-I
by	O
the	O
surgeon	O
(	O
n	O
=	O
25	O
)	O
or	O
as	O
ultrasonography	B-I
-	I-I
guided	I-I
BRSB	I-I
by	O
the	O
anesthesiologist	O
(	O
n	O
=	O
27	O
)	O
.	O

Scores	B-O
on	I-O
the	I-O
FACES	I-O
Pain	I-O
Rating	I-O
Scale	I-O
measured	O
at	O
10	O
-	O
minute	O
intervals	O
and	O
all	O
use	O
of	O
analgesic	O
medications	O
in	O
the	O
PACU	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
head	O
-	O
to	O
-	O
head	O
comparison	O
of	O
aripiprazole	B-I
and	O
risperidone	B-I
for	O
safety	O
and	O
treating	O
autistic	O
disorders	O
,	O
a	O
randomized	O
double	O
blind	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Fifty	B-P
nine	I-P
children	I-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
were	O
randomized	O
to	O
receive	O
either	O
aripiprazole	B-I
or	O
risperidone	B-I
for	O
2	O
months	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
change	O
in	O
Aberrant	B-O
Behavior	I-O
Checklist	I-O
(	I-O
ABC	I-O
)	I-O
scores	I-O
.	O

Adverse	B-O
events	I-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Riluzole	B-I
as	O
an	O
adjunctive	O
therapy	O
to	O
risperidone	B-I
for	O
the	O
treatment	O
of	O
irritability	O
in	O
children	B-P
with	I-P
autistic	I-P
disorder	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
10	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

The	O
study	O
enrolled	O
male	B-P
and	I-P
female	I-P
outpatients	I-P
aged	I-P
5	I-P
-	I-P
12	I-P
years	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
autistic	I-P
disorder	I-P
based	I-P
on	I-P
the	I-P
DSM	I-P
-	I-P
IV	I-P
-	I-P
TR	I-P
criteria	I-P
and	I-P
a	I-P
score	I-P
of	I-P
?12	I-P
on	I-P
the	I-P
Aberrant	I-P
Behavior	I-P
Checklist	I-P
-	I-P
Community	I-P
(	I-P
ABC	I-P
-	I-P
C	I-P
)	I-P
irritability	I-P
subscale	I-P
who	I-P
had	I-P
discontinued	I-P
other	I-P
medications	I-P
because	I-P
of	I-P
a	I-P
lack	I-P
of	I-P
efficacy	I-P
.	O

Subjects	O
received	O
riluzole	B-I
(	O
titrated	O
to	O
50	O
or	O
100	O
mg	O
/	O
day	O
based	O
on	O
bodyweight	O
)	O
or	O
placebo	B-C
in	O
addition	O
to	O
risperidone	B-I
(	O
titrated	O
up	O
to	O
2	O
or	O
3	O
mg	O
/	O
day	O
based	O
on	O
bodyweight	O
)	O
for	O
10	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Can	O
a	B-I
questionnaire	I-I
predict	O
vitamin	O
D	O
status	O
in	O
postmenopausal	B-P
women	I-P
?	O
.	O

METHODS	O
:	O
Women	O
completed	O
the	B-I
Vitamin	I-I
D	I-I
&	I-I
Sun	I-I
(	I-I
VIDSUN	I-I
)	I-I
questionnaire	I-I
and	O
we	O
measured	O
their	B-O
serum	I-O
25	I-O
-	I-O
hydrocyvitamin	I-O
D	I-O
(	I-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
)	I-O
levels	I-O
.	O

We	O
assessed	O
the	B-O
sensitivity	I-O
and	O
specificity	B-O
of	O
the	B-I
questionnaire	I-I
to	O
identify	O
VDI	B-O
(	I-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
level	I-O
<	I-O
50	I-O
nmol	I-O
/	I-O
l	I-O
)	O
.	O

Clinical	O
Research	O
Unit	O
,	O
University	O
of	O
Wisconsin	O
-	O
Madison	O
.	O

Postmenopausal	B-P
women	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Low	B-I
protein	I-I
provision	I-I
during	O
the	O
first	O
year	O
of	O
life	O
,	O
but	O
not	O
during	O
foetal	O
life	O
,	O
affects	O
metabolic	O
traits	O
,	O
organ	O
mass	O
development	O
and	O
growth	O
in	O
male	O
mink	O
(	O
Neovison	O
vison	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Tissue	B-I
microarray	I-I
in	O
a	O
subset	O
of	O
South	B-P
African	I-P
patients	I-P
with	I-P
DLBCL	I-P
.	O

METHODS	O
:	O
Tissue	O
samples	O
from	O
93	B-P
de	I-P
novo	I-P
diffuse	I-P
large	I-P
B	I-P
-	I-P
cell	I-P
lymphoma	I-P
patients	I-P
seen	I-P
between	I-P
1995	I-P
and	I-P
2009	I-P
randomly	O
receiving	O
either	O
standard	B-C
combination	I-C
chemotherapy	I-C
(	O
CHOP	B-C
,	O
n=48	O
)	O
or	O
the	B-I
identical	I-I
program	I-I
with	I-I
rituximab	I-I
(	O
n=45	O
)	O
were	O
subtyped	O
using	O
an	O
investigational	O
immunohistochemical	O
(	O
IHC	O
)	O
based	O
tissue	O
microarray	O
(	O
TMA	O
)	O
and	O
contrasted	O
to	O
the	O
approximately	O
corresponding	O
categories	O
as	O
defined	O
either	O
by	O
Hans	O
and	O
associates	O
using	O
a	O
three	O
marker	O
panel	O
into	O
germinal	O
or	O
non	O
-	O
germinal	O
centre	O
subtypes	O
or	O
by	O

Choi	O
and	O
colleagues	O
with	O
two	O
additional	O
antibodies	O
into	O
germinal	O
centre	O
(	O
GCB	O
)	O
or	O
activated	O
B	O
-	O
cells	O
(	O
ABC	O
)	O
.	O

Each	O
of	O
these	O
primary	O
subdivisions	O
was	O
further	O
evaluated	O
for	O
expression	B-O
of	I-O
BCL2	O
and	O
LMO2	B-O
both	O
of	O
which	O
are	O
recognised	O
to	O
predicate	O
response	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
study	O
to	O
evaluate	O
safety	O
and	O
tolerability	O
of	O
repeated	B-I
doses	I-I
of	I-I
tirasemtiv	I-I
in	O
patients	B-P
with	I-P
amyotrophic	I-P
lateral	I-P
sclerosis	I-P
.	O

METHODS	O
:	O
Tirasemtiv	B-I
was	O
given	O
as	O
a	O
single	O
daily	O
dose	O
up	O
to	O
375	O
mg	O
for	O
two	O
weeks	O
,	O
with	O
and	O
without	O
concomitant	O
riluzole	O
.	O

In	O
a	O
separate	O
cohort	O
,	O
an	O
ascending	O
dose	O
protocol	O
evaluated	O
a	O
total	O
dose	O
of	O
500	O
mg	O
daily	O
given	O
in	O
two	O
divided	O
doses	O
.	O

Safety	B-O
and	O
tolerability	B-O
were	O
assessed	O
,	O
as	O
well	O
as	O
measures	O
of	O
function	B-O
,	O
muscle	B-O
strength	I-O
and	O
endurance	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Assessment	O
of	O
global	B-I
functioning	I-I
in	O
adolescents	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
utility	O
of	O
the	O
Developmental	O
Disability	O
-	O
Child	O
Global	O
Assessment	O
Scale	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
person	B-I
-	I-I
centred	I-I
dementia	I-I
care	I-I
to	O
prevent	O
agitation	O
and	O
other	O
neuropsychiatric	O
symptoms	O
and	O
enhance	O
quality	O
of	O
life	O
in	O
nursing	B-P
home	I-P
patients	I-P
:	O
a	O
10	O
-	O
month	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
10	O
-	O
month	O
three	O
-	O
armed	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
compared	O
DCM	B-I
and	O
VPM	B-I
with	O
control	O
.	O

Of	O
624	O
nursing	O
home	O
patients	O
with	O
dementia	O
,	O
446	O
completed	O
follow	O
-	O
up	O
assessments	O
.	O

The	O
primary	O
outcome	O
was	O
the	O
change	O
on	O
the	B-O
Brief	I-O
Agitation	I-O
Rating	I-O
Scale	I-O
(	I-O
BARS	I-O
)	I-O
.	O

Secondary	O
outcomes	O
were	O
changes	O
on	O
the	B-O
10	I-O
-	I-O
item	I-O
version	I-O
of	I-O
the	I-O
Neuropsychiatric	I-O
Inventory	I-O
Questionnaire	I-O
(	I-O
NPI	I-O
-	I-O
Q	I-O
)	I-O
,	O
the	B-O
Cornell	I-O
Scale	I-O
for	I-O
Depression	I-O
in	I-O
Dementia	I-O
(	I-O
CSDD	I-O
)	I-O
and	O
the	B-O
Quality	I-O
of	I-O
Life	I-O
in	I-O
Late	I-O
-	I-O
Stage	I-O
Dementia	I-O
(	I-O
QUALID	I-O
)	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Baseline	O
factors	O
predicting	O
placebo	B-I
response	O
to	O
treatment	O
in	O
children	B-P
and	I-P
adolescents	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
multisite	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Randomized	O
clinical	O
trial	O
of	O
citalopram	O
hydrobromide	O
for	O
children	O
and	O
adolescents	O
with	O
autism	O
spectrum	O
disorders	O
and	O
prominent	O
repetitive	O
behavior	O
.	O

Baseline	O
data	O
at	O
study	O
entry	O
were	O
examined	O
with	O
respect	O
to	O
final	O
outcome	O
to	O
determine	O
if	O
response	O
predictors	O
could	O
be	O
identified	O
.	O

A	B-P
total	I-P
of	I-P
149	I-P
children	I-P
and	I-P
adolescents	I-P
5	I-P
to	I-P
17	I-P
years	I-P
of	I-P
age	I-P
(	I-P
mean	I-P
[	I-P
SD	I-P
]	I-P
age	I-P
,	I-P
9	I-P
.	I-P
4	I-P
[	I-P
3	I-P
.	I-P
1	I-P
]	I-P
years	I-P
)	I-P
from	O
6	O
academic	O
centers	O
were	O
randomly	O
assigned	O
to	O
citalopram	B-I
(	O
n	O
=	O
73	O
)	O
or	O
placebo	B-I
(	O
n	O
=	O
76	O
)	O
.	O

Participants	O
had	O
autistic	O
disorder	O
,	O
Asperger	O
syndrome	O
,	O
or	O
pervasive	O
developmental	O
disorder	O
,	O
not	O
otherwise	O
specified	O
;	O
had	O
illness	O
severity	O
ratings	O
that	O
were	O
moderate	O
or	O
more	O
than	O
moderate	O
on	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Severity	O
scale	O
;	O
and	O
scored	O
moderate	O
or	O
more	O
than	O
moderate	O
on	O
compulsive	O
behaviors	O
measured	O
with	O
the	O
modified	O
Children	O
'	O
s	O
Yale	O
-	O
Brown	O
Obsessive	O
-	O
Compulsive	O
Scale	O
.	O

Twelve	O
weeks	O
of	O
treatment	O
with	O
citalopram	B-I
(	O
10	O
mg	O
/	O
5	O
mL	O
)	O
or	O
placebo	B-C
.	O

The	O
mean	O
(	O
SD	O
)	O
maximum	O
dose	O
of	O
citalopram	B-I
was	O
16	O
.	O
5	O
(	O
6	O
.	O
5	O
)	O
mg	O
by	O
mouth	O
daily	O
(	O
maximum	O
dose	O
,	O
20	O
mg	O
/	O
d	O
)	O
.	O

A	O
positive	O
response	O
was	O
defined	O
as	O
having	O
a	O
score	O
of	O
at	O
least	O
much	O
improved	O
on	O
the	O
Clinical	O
Global	O
Impression	O
-	O
Improvement	O
scale	O
at	O
week	O
12	O
.	O

Baseline	B-O
measures	I-O
included	O
demographic	B-O
(	O
sex	B-O
,	O
age	B-O
,	O
weight	B-O
,	O
and	O
pubertal	B-O
status	I-O
)	O
,	O
clinical	B-O
,	O
and	O
family	B-O
measures	I-O
.	O

Clinical	B-O
variables	I-O
included	O
baseline	O
illness	B-O
severity	I-O
ratings	I-O
(	O
the	B-O
Aberrant	I-O
Behavior	I-O
Checklist	I-O
,	O
the	B-O
Child	I-O
and	I-O
Adolescent	I-O
Symptom	I-O
Inventory	I-O
,	O
the	B-O
Vineland	I-O
Adaptive	I-O
Behavior	I-O
Scales	I-O
,	O
the	B-O
Repetitive	I-O
Behavior	I-O
Scale	I-O
-	I-O
Revised	I-O
,	O
and	O
the	B-O
Children	I-O
'	I-O
s	I-O
Yale	I-O
-	I-O
Brown	I-O
Obsessive	I-O
-	I-O
Compulsive	I-O
Scale	I-O
)	O
.	O

Family	B-O
measures	I-O
included	O
the	B-O
Caregiver	I-O
Strain	I-O
Questionnaire	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
shortened	I-I
versus	O
standard	B-C
matched	I-C
postpartum	I-C
magnesium	I-C
sulphate	I-C
regimen	I-C
in	O
the	O
treatment	O
of	O
eclampsia	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
The	B-O
maternal	I-O
and	O
fetal	B-O
outcomes	I-O
were	O
compared	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
recurrence	B-O
of	I-O
fits	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Local	B-I
contextual	I-I
processing	I-I
in	O
major	O
depressive	O
disorder	O
.	O

METHODS	O
:	O
We	O
recorded	O
EEG	O
in	O
15	O
MDD	O
patients	O
and	O
14	O
age	O
-	O
matched	O
controls	O
.	O

Recording	O
blocks	O
consisted	O
of	O
targets	O
preceded	O
by	O
randomized	O
sequences	O
of	O
standards	O
and	O
by	O
sequences	O
of	O
standards	O
that	O
included	O
a	O
predictive	O
sequence	O
signaling	O
the	O
occurrence	O
of	O
a	O
subsequent	O
target	O
event	O
.	O

-DOCSTART-	O

Title	O
:	O
Group	B-I
cognitive	I-I
behavioural	I-I
therapy	I-I
and	O
group	B-I
recreational	I-I
activity	I-I
for	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
a	O
preliminary	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
preliminary	O
randomized	O
controlled	O
open	O
trial	O
with	O
a	O
parallel	O
design	O
developed	O
two	O
group	O
interventions	O
for	O
adults	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
and	I-P
intelligence	I-P
within	I-P
the	I-P
normal	I-P
range	I-P
:	O
cognitive	B-I
behavioural	I-I
therapy	I-I
and	O
recreational	B-I
activity	I-I
.	O

Both	O
interventions	O
comprised	O
36	O
weekly	O
3	O
-	O
h	O
sessions	O
led	O
by	O
two	O
therapists	O
in	O
groups	O
of	O
6	O
-	O
8	O
patients	O
.	O

A	B-P
total	I-P
of	I-P
68	I-P
psychiatric	I-P
patients	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
participated	O
in	O
the	O
study	O
.	O

Outcome	O
measures	O
were	O
Quality	B-O
of	I-O
Life	I-O
Inventory	I-O
,	O
Sense	B-O
of	I-O
Coherence	I-O
Scale	I-O
,	O
Rosenberg	B-O
Self	I-O
-	I-O
Esteem	I-O
Scale	I-O
and	O
an	O
exploratory	O
analysis	O
on	O
measures	B-O
of	I-O
psychiatric	I-O
health	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Group	B-I
therapy	I-I
for	O
anxiety	O
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
32	I-P
children	I-P
aged	I-P
9	I-P
-	I-P
13	I-P
years	I-P
were	O
randomised	O
to	O
immediate	B-I
or	O
delayed	B-I
therapy	I-I
using	O
the	B-I
'	I-I
Exploring	I-I
Feelings	I-I
'	I-I
manual	I-I
(	O
Attwood	O
,	O
2004	O
)	O
.	O

Child	O
and	O
parent	O
groups	O
were	O
run	O
in	O
parallel	O
,	O
for	O
seven	O
weekly	O
sessions	O
,	O
under	O
the	O
supervision	O
of	O
experienced	O
psychologists	O
.	O

The	O
primary	O
blinded	O
outcome	O
measures	O
addressed	O
change	O
in	O
overall	B-O
functioning	I-O
and	O
in	O
severity	B-O
of	I-O
the	I-O
primary	I-O
anxiety	I-O
diagnosis	I-O
after	O
3	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Sequential	B-I
therapy	I-I
versus	O
standard	B-C
triple	I-C
-	I-C
drug	I-C
therapy	I-C
for	O
Helicobacter	O
pylori	O
eradication	O
:	O
a	O
randomized	O
study	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
open	O
-	O
labeled	O
,	O
prospective	O
controlled	O
trial	O
comparing	O
sequential	B-I
vs	O
.	O
standard	B-C
triple	I-C
-	I-C
drug	I-C
therapy	I-C
was	O
carried	O
out	O
at	O
Lokmanya	O
Tilak	O
Municipal	O
General	O
Hospital	O
,	O
Mumbai	O
.	O

Two	B-P
hundred	I-P
and	I-P
thirty	I-P
-	I-P
one	I-P
patients	I-P
with	I-P
dyspepsia	I-P
were	O
randomized	O
to	O
a	B-I
10	I-I
-	I-I
day	I-I
sequential	I-I
regimen	I-I
(	O
40	B-I
mg	I-I
of	I-I
pantoprazole	I-I
,	O
1	B-I
g	I-I
of	I-I
amoxicillin	I-I
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
first	O
5	O
days	O
,	O
followed	O
by	O
40	B-I
mg	I-I
of	I-I
pantoprazole	I-I
,	O
500	B-I
mg	I-I
of	I-I
clarithromycin	I-I
,	O
and	O
500	B-I
mg	I-I
of	I-I
tinidazole	I-I
,	O
each	O
administered	O
twice	O
daily	O
for	O
the	O
remaining	O
5	O
days	O
)	O
or	O
to	O
standard	B-C
14	I-C
-	I-C
day	I-C
therapy	I-C
(	O
40	B-C
mg	I-C
of	I-C
pantoprazole	I-C
,	O
500	B-C
mg	I-C
of	I-C
clarithromycin	I-C
,	O
and	O
1	B-C
g	I-C
of	I-C
amoxicillin	I-C
,	O
each	O
administered	O
twice	O
daily	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Hypotension	O
in	O
response	O
to	O
iloprost	B-I
,	O
a	B-I
prostacyclin	I-I
analogue	I-I
.	O

-DOCSTART-	O

Title	O
:	O
An	O
intervention	O
for	O
sensory	O
difficulties	O
in	O
children	B-P
with	I-P
autism	I-P
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Diagnosis	O
of	O
autism	O
was	O
confirmed	O
using	O
gold	O
standard	O
measures	O
.	O

-DOCSTART-	O

Title	O
:	O
Humoral	O
immunity	O
after	O
kidney	O
transplantation	O
:	O
impact	O
of	O
two	B-I
randomized	I-I
immunosuppressive	I-I
protocols	I-I
.	O

METHODS	O
:	O
We	O
performed	O
a	O
post	O
-	O
hoc	O
analysis	O
on	O
307	B-P
kidney	I-P
transplant	I-P
recipients	I-P
included	O
in	O
a	O
prospective	O
randomized	O
trial	O
comparing	O
tacrolimus	B-I
/	O
mycophenolate	B-I
mofetil	I-I
(	O
Tac	B-I
/	O
MMF	B-I
)	O
vs	O
.	O
cyclosporine	B-I
/	O
azathioprine	B-I
(	O
CsA	B-I
/	O
AZA	B-I
)	O
,	O
both	O
used	O
with	O
antithymocyte	O
globulin	O
induction	O
and	O
steroids	O
.	O

Humoral	B-O
parameters	I-O
were	O
analyzed	O
at	O
D0	O
,	O
D15	O
,	O
and	O
M12	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
augmented	O
sensorimotor	O
input	O
on	O
learning	B-I
verbal	I-I
and	O
nonverbal	O
tasks	O
among	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

METHODS	O
:	O
Thirty	B-P
-	I-P
four	I-P
children	I-P
,	I-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
,	I-P
ages	I-P
4	I-P
-	I-P
14	I-P
years	I-P
,	O
were	O
matched	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
conditions	O
for	O
learning	B-I
a	I-I
novel	I-I
juice	I-I
-	I-I
making	I-I
task	I-I
and	O
producing	B-I
two	I-I
novel	I-I
words	I-I
about	I-I
the	I-I
event	I-I
.	O

Seventeen	O
sighted	O
children	O
were	O
manually	O
guided	O
to	O
perform	O
the	O
task	O
and	O
tactually	O
prompted	O
during	O
imitated	O
productions	O
of	O
novel	O
words	O
for	O
the	O
event	O
.	O

Their	O
matched	O
controls	O
heard	O
the	B-C
novel	I-C
words	I-C
and	O
watched	O
the	B-C
juice	I-C
-	I-C
making	I-C
task	I-C
being	I-C
performed	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
controlled	O
effectiveness	O
trial	O
of	O
executive	B-I
function	I-I
intervention	I-I
for	O
children	B-P
on	I-P
the	I-P
autism	I-P
spectrum	I-P
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
effectiveness	O
of	O
UOT	B-I
compared	O
with	O
a	B-I
social	I-I
skills	I-I
intervention	I-I
(	I-I
SS	I-I
)	I-I
,	O
3rd	B-P
-	I-P
5th	I-P
graders	I-P
with	I-P
ASD	I-P
(	I-P
mean	I-P
IQ	I-P
=	I-P
108	I-P
;	I-P
UOT	I-P
n	I-P
=	I-P
47	I-P
;	I-P
SS	I-P
n	I-P
=	I-P
20	I-P
)	I-P
received	O
interventions	O
delivered	O
by	O
school	O
staff	O
in	O
small	O
group	O
sessions	O
.	O

Students	O
were	O
matched	O
for	O
gender	O
,	O
age	O
,	O
race	O
,	O
IQ	O
,	O
ASD	O
symptomotolgy	O
,	O
medication	O
status	O
,	O
and	O
parents	O
'	O
education	O
.	O

Interventions	O
were	O
matched	O
for	O
'	O
dose	O
'	O
of	O
intervention	O
and	O
training	O
.	O

Measures	O
of	O
pre	O
-	O
post	O
change	O
included	O
classroom	B-O
observations	I-O
,	O
parent	B-O
/	I-O
teacher	I-O
report	I-O
,	O
and	O
direct	B-O
child	I-O
measures	I-O
of	I-O
problem	I-O
-	I-O
solving	I-O
,	O
EF	B-O
,	O
and	O
social	B-O
skills	I-O
.	O

Schools	O
were	O
randomized	O
and	O
evaluators	O
,	O
but	O
not	O
parents	O
or	O
teachers	O
,	O
were	O
blinded	O
to	O
intervention	O
type	O
.	O

-DOCSTART-	O

Title	O
:	O
Influence	O
of	O
two	B-I
different	I-I
doses	I-I
of	I-I
antithymocyte	I-I
globulin	I-I
in	O
patients	B-P
with	I-P
standard	I-P
-	I-P
risk	I-P
disease	I-P
following	I-P
haploidentical	I-P
transplantation	I-P
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
the	B-I
different	I-I
doses	I-I
of	I-I
antithymocyte	I-I
globulin	I-I
(	I-I
ATG	I-I
)	I-I
on	O
the	B-O
incidence	I-O
of	I-O
acute	I-O
GVHD	I-O
among	O
patients	B-P
receiving	I-P
hematopoietic	I-P
SCT	I-P
without	I-P
ex	I-P
vivo	I-P
T	I-P
-	I-P
cell	I-P
-	I-P
depletion	I-P
from	I-P
haploidentical	I-P
donors	I-P
,	O
224	B-P
patients	I-P
with	I-P
standard	I-P
-	I-P
risk	I-P
hematological	I-P
malignancy	I-P
were	O
randomized	O
in	O
this	O
study	O
.	O

One	O
hundred	O
and	O
twelve	O
patients	O
received	O
6	B-I
mg	I-I
/	I-I
kg	I-I
ATG	I-I
,	O
whereas	O
the	O
remaining	O
patients	O
received	O
10	B-I
mg	I-I
/	I-I
kg	I-I
ATG	I-I
.	O

This	O
study	O
was	O
registered	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
chictr	O
.	O
org	O
as	O
No	O
.	O

ChiCTR	O
-	O
TRC	O
-	O
11001761	O
.	O

-DOCSTART-	O

Title	O
:	O
An	O
intervention	O
to	O
decrease	O
stigma	O
in	O
young	B-P
adults	I-P
with	I-P
sickle	I-P
cell	I-P
disease	I-P
.	O

METHODS	O
:	O
Young	B-P
adults	I-P
with	I-P
SCD	I-P
ages	I-P
18	I-P
to	I-P
35	I-P
years	I-P
(	O
n	O
=	O
90	O
)	O
were	O
randomized	O
to	O
either	O
the	B-I
care	I-I
-	I-I
seeking	I-I
intervention	I-I
(	I-I
CSI	I-I
)	I-I
or	O
an	B-C
attention	I-C
control	O
group	O
that	O
participated	O
in	O
life	O
review	O
interviews	O
.	O

The	O
two	O
groups	O
were	O
compared	O
by	O
t	O
tests	O
and	O
longitudinal	O
data	O
analyses	O
on	O
the	O
change	O
from	O
baseline	O
to	O
the	O
last	O
time	O
point	O
in	O
total	B-O
health	I-O
-	I-O
related	I-O
stigma	I-O
and	O
health	B-O
-	I-O
related	I-O
stigma	I-O
by	O
doctors	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	B-I
-	I-I
dose	I-I
versus	O
standard	B-C
-	I-C
dose	I-C
gemcitabine	I-C
infusion	I-C
and	O
cisplatin	B-C
for	O
patients	B-P
with	I-P
advanced	I-P
bladder	I-P
cancer	I-P
:	O
a	O
randomized	O
phase	O
II	O
trial	O
-	O
an	O
update	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
and	I-P
twenty	I-P
untreated	I-P
patients	I-P
with	I-P
stage	I-P
III	I-P
/	I-P
IV	I-P
bladder	I-P
cancer	I-P
were	O
randomized	O
to	O
receive	O
either	O
gemcitabine	B-I
(	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
6	O
-	O
h	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
and	O
cisplatin	B-I
(	O
70	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
on	O
day	O
2	O
every	O
21	O
-	O
day	O
cycle	O
(	O
arm	O
1	O
)	O
or	O
gemcitabine	B-I
(	O
1	O
,	O
250	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
30	O
-	O
min	O
infusion	O
on	O
days	O
1	O
and	O
8	O
,	O
with	O
the	B-I
same	I-I
dose	I-I
of	I-I
cisplatin	I-I
(	O
arm	O
2	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Population	O
pharmacokinetic	O
/	O
pharmacodynamic	O
analysis	O
of	O
the	B-I
DPP	I-I
-	I-I
4	I-I
inhibitor	I-I
linagliptin	I-I
in	O
Japanese	B-P
patients	I-P
with	I-P
type	I-P
2	I-P
diabetes	I-P
mellitus	I-P
.	O

METHODS	O
:	O
Linagliptin	B-O
plasma	I-O
concentration	I-O
and	O
DPP	B-O
-	I-O
4	I-O
inhibition	I-O
measurements	I-O
from	O
a	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
multiple	O
(	O
28	O
days	O
)	O
dose	O
trial	O
that	O
included	O
36	B-P
T2DM	I-P
patients	I-P
(	I-P
18	I-P
patients	I-P
each	I-P
in	I-P
2	I-P
.	I-P
5	I-P
mg	I-P
and	I-P
10	I-P
mg	I-P
dose	I-P
group	I-P
)	I-P
were	O
used	O
for	O
analysis	O
.	O

Modeling	O
was	O
performed	O
using	O
FOCE	O
INTERACTION	O
estimation	O
method	O
implemented	O
in	O
NONMEM	O
V	O
.	O

The	B-O
linagliptin	I-O
plasma	I-O
concentration	I-O
-	I-O
and	O
DPP	B-O
-	I-O
4	I-O
inhibition	I-O
-	I-O
time	I-O
profiles	I-O
were	O
simulated	O
for	O
Japanese	B-P
patients	I-P
receiving	O
5	B-I
mg	I-I
linagliptin	I-I
once	O
daily	O
by	O
the	O
model	O
established	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
controlled	O
trial	O
of	O
the	B-I
Korean	I-I
version	I-I
of	I-I
the	I-I
PEERS	I-I
(	I-I
?	I-I
)	I-I
parent	I-I
-	I-I
assisted	I-I
social	I-I
skills	I-I
training	I-I
program	I-I
for	O
teens	B-P
with	I-P
ASD	I-P
.	O

METHODS	O
:	O
Items	O
identified	O
as	O
culturally	O
sensitive	O
were	O
surveyed	O
by	O
447	O
middle	O
school	O
students	O
,	O
and	O
material	O
was	O
modified	O
accordingly	O
.	O

Participants	O
included	O
47	B-P
teens	I-P
between	I-P
12	I-P
and	I-P
18	I-P
years	I-P
of	I-P
age	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
ASD	I-P
and	I-P
a	I-P
verbal	I-P
intelligence	I-P
quotient	I-P
(	I-P
IQ	I-P
)	I-P
??	I-P
65	I-P
.	O

Eligible	O
teens	O
were	O
randomly	O
assigned	O
to	O
a	O
treatment	O
group	O
(	O
TG	O
)	O
or	O
delayed	O
treatment	O
control	O
group	O
(	O
CG	O
)	O
.	O

Primary	O
outcome	O
measures	O
included	O
questionnaires	B-O
and	O
direct	B-O
observations	I-O
quantifying	O
social	B-O
ability	I-O
and	O
problems	B-O
directly	I-O
related	I-O
to	I-O
ASD	I-O
.	O

Secondary	O
outcome	O
measures	O
included	O
scales	O
for	O
depressive	B-O
symptoms	I-O
,	O
anxiety	B-O
,	O
and	O
other	B-O
behavioral	I-O
problems	I-O
.	O

Rating	O
scales	O
for	O
parental	B-O
depressive	I-O
symptoms	I-O
and	O
anxiety	B-O
were	O
examined	O
to	O
detect	O
changes	O
in	O
parental	O
psychosocial	O
functioning	O
throughout	O
the	B-I
PEERS	I-I
(	I-I
?	I-I
)	I-I
treatment	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Management	O
of	O
large	O
bowel	O
obstruction	O
with	O
self	B-I
-	I-I
expanding	I-I
metal	I-I
stents	I-I
.	O

A	O
multicentre	O
retrospective	O
study	O
of	O
factors	O
determining	O
outcome	O
.	O

METHODS	O
:	O
A	O
regional	O
programme	O
of	O
colonic	B-I
stenting	I-I
for	O
large	O
bowel	O
obstruction	O
,	O
in	O
five	O
UK	O
centres	O
from	O
2005	O
to	O
2010	O
was	O
evaluated	O
for	O
outcome	O
including	O
technical	B-O
and	O
clinical	B-O
success	I-O
,	O
survival	B-O
,	O
complications	B-O
and	O
reoperation	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Alleviating	O
social	O
avoidance	O
:	O
effects	O
of	O
single	B-I
dose	I-I
testosterone	I-I
administration	O
on	O
approach	O
-	O
avoidance	O
action	O
.	O

METHODS	O
:	O
The	O
present	O
study	O
sets	O
out	O
to	O
test	O
the	O
effects	O
of	O
testosterone	B-I
administration	O
in	O
healthy	B-P
female	I-P
volunteers	I-P
using	I-P
an	I-P
objective	I-P
implicit	I-P
measure	I-P
of	I-P
social	I-P
motivational	I-P
behavior	I-P
:	O
the	B-O
social	I-O
Approach	I-O
-	I-O
Avoidance	I-O
Task	I-O
,	O
a	O
reaction	O
time	O
task	O
requiring	O
participants	O
to	O
approach	O
or	O
avoid	O
visually	O
presented	O
emotional	O
(	O
happy	O
,	O
angry	O
,	O
and	O
neutral	O
)	O
faces	O
.	O

-DOCSTART-	O

Title	O
:	O
Dentists	O
United	O
to	O
Extinguish	O
Tobacco	O
(	O
DUET	O
)	O
:	O
a	O
study	O
protocol	O
for	O
a	O
cluster	O
randomized	O
,	O
controlled	O
trial	O
for	O
enhancing	O
implementation	O
of	O
clinical	O
practice	O
guidelines	O
for	O
treating	O
tobacco	O
dependence	O
in	O
dental	O
care	O
settings	O
.	O

METHODS	O
:	O
Guided	O
by	O
a	O
multi	O
-	O
level	O
,	O
conceptual	O
framework	O
that	O
emphasizes	O
changes	O
in	O
provider	O
beliefs	O
and	O
organizational	O
characteristics	O
as	O
drivers	O
of	O
improvement	O
in	O
tobacco	O
treatment	O
delivery	O
,	O
the	O
current	O
protocol	O
will	O
use	O
a	O
cluster	O
,	O
randomized	O
design	O
and	O
multiple	O
data	O
sources	O
(	O
patient	O
exit	O
interviews	O
,	O
provider	O
surveys	O
,	O
site	O
observations	O
,	O
chart	O
audits	O
,	O
and	O
semi	O
-	O
structured	O
provider	O
interviews	O
)	O
to	O
study	O
the	O
process	O
of	O
implementing	O
clinical	O
practice	O
guidelines	O
for	O
treating	O
tobacco	O
dependence	O
in	O
18	O
public	O

dental	O
care	O
clinics	O
in	O
New	O
York	O
City	O
.	O

The	O
specific	O
aims	O
of	O
this	O
comparative	O
-	O
effectiveness	O
research	O
trial	O
are	O
to	O
:	O
compare	O
the	O
effectiveness	O
of	O
three	B-I
promising	I-I
strategies	I-I
for	I-I
implementation	I-I
of	I-I
tobacco	I-I
use	I-I
treatment	I-I
guidelines	I-I
-	O
staff	B-I
training	I-I
and	O
current	B-I
best	I-I
practices	I-I
(	I-I
CBP	I-I
)	I-I
,	O
CBP	B-I
+	O
provider	B-I
performance	I-I
feedback	I-I
(	I-I
PF	I-I
)	I-I
,	O
and	O
CBP	B-I
+	O
PF	B-I
+	O
provider	B-I
reimbursement	I-I
for	I-I
delivery	I-I
of	I-I
tobacco	I-I
cessation	I-I
treatment	I-I
(	I-I
pay	I-I
-	I-I
for	I-I
-	I-I
performance	I-I
,	I-I
or	I-I
P4P	I-I
)	I-I
;	O
examine	O
potential	O
theory	O
-	O
driven	O
mechanisms	O
hypothesized	O
to	O
explain	O
the	O
comparative	O
effectiveness	O
of	O
three	O
strategies	O

for	O
implementation	O
;	O
and	O
identify	O
baseline	O
organizational	O
factors	O
that	O
influence	O
the	O
implementation	O
of	O
evidence	O
-	O
based	O
tobacco	O
use	O
treatment	O
practices	O
in	O
dental	O
clinics	O
.	O

The	O
primary	O
outcome	O
is	O
change	O
in	O
providers	B-O
'	I-O
tobacco	I-O
treatment	I-O
practices	I-O
and	O
the	O
secondary	O
outcomes	O
are	O
cost	B-O
per	I-O
quit	I-O
,	O
use	B-O
of	I-O
tobacco	I-O
cessation	I-O
treatments	I-O
,	O
quit	B-O
attempts	I-O
,	O
and	O
smoking	B-O
abstinence	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
lowering	B-I
LDL	I-I
cholesterol	I-I
on	O
vascular	O
access	O
patency	O
:	O
post	O
hoc	O
analysis	O
of	O
the	O
Study	O
of	O
Heart	O
and	O
Renal	O
Protection	O
.	O

METHODS	O
:	O
The	O
Study	O
of	O
Heart	O
and	O
Renal	O
Protection	O
(	O
SHARP	O
)	O
randomized	O
patients	B-P
with	I-P
CKD	I-P
to	O
20	B-I
mg	I-I
simvastatin	I-I
plus	O
10	B-I
mg	I-I
ezetimibe	I-I
daily	O
versus	O
matching	B-C
placebo	I-C
.	O

This	O
study	O
aimed	O
to	O
explore	O
the	O
effects	O
of	O
treatment	O
on	O
vascular	B-O
access	I-O
occlusive	I-O
events	I-O
,	O
defined	O
as	O
any	B-O
access	I-O
revision	I-O
procedure	I-O
,	O
access	B-O
thrombosis	I-O
,	O
removal	B-O
of	I-O
an	I-O
old	I-O
dialysis	I-O
access	I-O
,	O
or	O
formation	B-O
of	I-O
new	I-O
permanent	I-O
dialysis	I-O
access	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Factors	O
associated	O
with	O
low	B-I
consumption	I-I
of	I-I
fruits	I-I
and	O
vegetables	B-I
by	O
preschoolers	B-P
of	I-P
low	I-P
socio	I-P
-	I-P
economic	I-P
level	I-P
.	O

METHODS	O
:	O
This	O
was	O
a	O
cohort	O
study	O
nested	O
in	O
a	O
randomized	O
field	O
trial	O
.	O

Data	O
collection	O
was	O
performed	O
through	O
structured	O
questionnaires	O
to	O
obtain	O
demographic	O
and	O
dietary	O
data	O
,	O
combined	O
with	O
two	O
24	O
-	O
hour	O
recalls	O
in	O
the	O
age	O
groups	O
12	O
-	O
16	O
months	O
and	O
again	O
at	O
2	O
-	O
3	O
years	O
of	O
age	O
.	O

Data	O
on	O
the	B-I
consumption	I-I
of	I-I
one	I-I
daily	I-I
serving	I-I
of	I-I
fruits	I-I
(	O
80	O
g	O
)	O
and	O
vegetables	B-I
(	O
60	O
g	O
)	O
were	O
evaluated	O
,	O
as	O
well	O
as	O
consumption	B-I
of	I-I
non	I-I
-	I-I
recommended	I-I
foods	I-I
such	O
as	O
candy	B-I
,	O
chocolate	B-I
,	O
and	O
soft	B-I
drinks	I-I
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
Poisson	O
regression	O
with	O
robust	O
estimation	O
.	O

-DOCSTART-	O

Title	O
:	O
Weight	O
loss	O
maintenance	O
in	O
overweight	B-P
subjects	I-P
on	O
ad	B-I
libitum	I-I
diets	I-I
with	I-I
high	I-I
or	O
low	B-I
protein	I-I
content	I-I
and	O
glycemic	B-I
index	I-I
:	O
the	O
DIOGENES	O
trial	O
12	O
-	O
month	O
results	O
.	O

METHODS	O
:	O
After	O
an	O
8	O
-	O
week	O
low	O
-	O
calorie	O
diet	O
(	O
LCD	O
)	O
,	O
256	B-P
adults	I-P
(	I-P
body	I-P
mass	I-P
index	I-P
>	I-P
27	I-P
kg	I-P
m	I-P
(	I-P
-	I-P
)	I-P
(	I-P
2	I-P
)	I-P
)	I-P
were	O
randomized	O
to	O
five	B-I
ad	I-I
libitum	I-I
diets	I-I
for	O
12	O
months	O
:	O
high	B-I
P	I-I
/	O
LGI	B-I
(	O
HP	B-I
/	O
LGI	B-I
)	O
,	O
HP	B-I
/	O
high	B-I
GI	I-I
(	O
HP	B-I
/	O
HGI	B-I
)	O
,	O
low	B-I
P	I-I
/	O
LGI	B-I
(	O
LP	B-I
/	O
LGI	B-I
)	O
,	O
LP	B-I
/	O
HGI	B-I
and	O
a	B-C
control	I-C
diet	I-C
.	O

During	O
the	O
first	O
6	O
months	O
,	O
foods	O
were	O
provided	O
for	O
free	O
through	O
a	O
shop	O
system	O
and	O
during	O
the	O
whole	O
12	O
-	O
month	O
period	O
,	O
subjects	O
received	O
guidance	O
by	O
a	O
dietician	O
.	O

Primary	O
outcome	O
variable	O
was	O
the	O
change	O
in	O
body	B-O
weight	I-O
over	O
the	O
12	O
-	O
month	O
intervention	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
clinical	O
trial	O
comparing	O
mitoxantrone	B-I
with	O
doxorubicin	B-I
in	O
previously	B-P
treated	I-P
patients	I-P
with	I-P
metastatic	I-P
breast	I-P
cancer	I-P
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
twenty	I-P
-	I-P
five	I-P
women	I-P
with	I-P
metastatic	I-P
adenocarcinoma	I-P
of	I-P
the	I-P
breast	I-P
who	I-P
had	I-P
failed	I-P
one	I-P
prior	I-P
chemotherapeutic	I-P
regimen	I-P
for	I-P
advanced	I-P
disease	I-P
were	O
randomized	O
to	O
receive	O
14	B-I
mg	I-I
/	I-I
m2	I-I
of	I-I
mitoxantrone	I-I
or	O
75	B-I
mg	I-I
/	I-I
m2	I-I
of	I-I
doxorubicin	I-I
intravenously	O
(	O
IV	O
)	O
every	O
3	O
weeks	O
.	O

Enrollment	O
was	O
closed	O
on	O
October	O
31	O
,	O
1984	O
,	O
after	O
165	O
patients	O
were	O
randomized	O
to	O
mitoxantrone	B-I
and	O
160	O
patients	O
to	O
doxorubicin	B-I
.	O

Patients	O
randomized	O
to	O
the	O
two	O
treatment	O
groups	O
were	O
compared	O
for	O
response	B-O
rate	I-O
,	O
duration	B-O
of	I-O
response	I-O
,	O
time	B-O
to	I-O
progression	I-O
or	O
death	B-O
,	O
time	B-O
to	I-O
treatment	I-O
failure	I-O
(	I-O
TTF	I-O
)	I-O
,	O
and	O
survival	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Hemodialysis	O
catheter	O
design	O
and	O
catheter	O
performance	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Single	O
-	O
center	O
randomized	O
clinical	O
trial	O
.	O

302	B-P
hemodialysis	I-P
patients	I-P
who	I-P
required	I-P
a	I-P
tunneled	I-P
cuffed	I-P
catheter	I-P
as	I-P
temporary	I-P
or	I-P
definite	I-P
vascular	I-P
access	I-P
.	O

Palindrome	B-I
Symmetric	I-I
Tip	I-I
Dialysis	I-I
Catheter	I-I
or	O
HemoStar	B-I
Long	I-I
-	I-I
Term	I-I
Hemodialysis	I-I
Catheter	I-I
.	O

The	O
primary	O
end	O
point	O
was	O
primary	B-O
assisted	I-O
patency	I-O
.	O

Secondary	O
end	O
points	O
were	O
incidence	B-O
of	I-O
catheter	I-O
-	I-O
related	I-O
bloodstream	I-O
infections	I-O
(	I-O
CRBSIs	I-O
)	I-O
,	O
thrombosis	B-O
,	O
and	O
2	B-O
indicators	I-O
of	I-O
rheologic	I-O
function	I-O
:	O
mean	B-O
effective	I-O
blood	I-O
flow	I-O
rate	I-O
and	O
urokinase	B-O
use	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
mixed	I-I
kinesio	I-I
taping	I-I
-	I-I
compression	I-I
technique	I-I
on	O
quality	O
of	O
life	O
and	O
clinical	O
and	O
gait	O
parameters	O
in	O
postmenopausal	B-P
women	I-P
with	I-P
chronic	I-P
venous	I-P
insufficiency	I-P
:	O
double	O
-	O
blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Double	O
-	O
blinded	O
,	O
randomized	O
controlled	O
trial	O
.	O

Clinical	O
setting	O
.	O

Consecutive	B-P
postmenopausal	I-P
women	I-P
(	I-P
N=130	I-P
;	I-P
mean	I-P
age	I-P
	I-P
SD	I-P
,	I-P
65	I-P
.	I-P
4414	I-P
.	I-P
7y	I-P
)	I-P
with	I-P
mild	I-P
CVI	I-P
.	O

No	O
participant	O
withdrew	O
because	O
of	O
adverse	O
effects	O
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
either	O
(	O
1	O
)	O
an	O
experimental	O
group	O
to	O
receive	O
a	B-I
mixed	I-I
KT	I-I
-	I-I
compression	I-I
treatment	I-I
following	O
KT	B-I
recommendations	I-I
for	I-I
gastrocnemius	I-I
muscle	I-I
enhancement	I-I
and	I-I
functional	I-I
correction	I-I
of	I-I
the	I-I
ankle	I-I
,	O
and	O
adding	O
2	B-I
tapes	I-I
to	I-I
simulate	I-I
traditional	I-I
compression	I-I
bandages	I-I
(	O
no	O
KT	O
guidelines	O
)	O
;	O
or	O
(	O
2	O
)	O
a	B-C
placebo	I-C
control	O
group	O
for	O
sham	B-C
KT	I-C
.	O

Both	O
interventions	O
were	O
performed	O
3	O
times	O
a	O
week	O
during	O
a	O
4	O
-	O
week	O
period	O
.	O

ROAM	B-O
,	O
gait	B-O
,	O
pain	B-O
,	O
perimeter	B-O
of	I-O
right	I-O
and	I-O
left	I-O
lower	I-O
limb	I-O
,	O
and	O
quality	B-O
of	I-O
life	I-O
were	O
assessed	O
at	O
baseline	O
and	O
48	O
hours	O
posttreatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
olanzapine	B-I
long	I-I
-	I-I
acting	I-I
injection	I-I
and	O
oral	B-I
olanzapine	I-I
:	O
a	O
2	O
-	O
year	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
in	O
outpatients	B-P
with	I-P
schizophrenia	I-P
.	O

METHODS	O
:	O
Outpatients	B-P
with	I-P
2	I-P
or	I-P
more	I-P
episodes	I-P
of	I-P
psychotic	I-P
worsening	I-P
in	I-P
the	I-P
past	I-P
24	I-P
months	I-P
with	I-P
Positive	I-P
and	I-P
Negative	I-P
Syndrome	I-P
Scale	I-P
total	I-P
score	I-P
of	I-P
lower	I-P
than	I-P
70	I-P
were	O
randomized	O
to	O
405	B-I
mg	I-I
/	I-I
4	I-I
weeks	I-I
of	I-I
olanzapine	I-I
LAI	I-I
(	O
n	O
=	O
264	O
)	O
or	O
10	B-I
mg	I-I
/	I-I
d	I-I
of	I-I
oral	I-I
olanzapine	I-I
(	O
n	O
=	O
260	O
)	O
for	O
2	O
years	O
of	O
open	O
-	O
label	O
treatment	O
.	O

Dosing	O
thereafter	O
was	O
flexible	O
(	O
150	O
-	O
405	O
mg	O
/	O
4	O
weeks	O
of	O
LAI	O
vs	O
5	O
-	O
20	O
mg	O
/	O
d	O
of	O
oral	O
)	O
.	O

Primary	O
outcome	O
was	O
time	B-O
to	I-O
all	I-O
-	I-O
cause	I-O
discontinuation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Impact	O
of	O
additional	O
counselling	O
sessions	B-I
through	I-I
phone	I-I
calls	I-I
on	O
smoking	O
cessation	O
outcomes	O
among	O
smokers	B-P
in	I-P
Penang	I-P
State	I-P
,	I-P
Malaysia	I-P
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
at	O
Quit	O
Smoking	O
Clinic	O
of	O
two	O
major	O
hospitals	O
in	O
Penang	O
,	O
Malaysia	O
.	O

All	B-P
the	I-P
eligible	I-P
smokers	I-P
who	I-P
attended	I-P
the	I-P
clinics	I-P
between	I-P
February	I-P
1st	I-P
and	I-P
October	I-P
31st	I-P
2012	I-P
were	O
invited	O
.	O

Participants	O
were	O
randomly	O
assigned	O
by	O
using	O
urn	B-I
design	I-I
method	I-I
either	O
to	O
receive	O
the	B-C
usual	I-C
care	I-C
that	O
followed	O
in	O
the	O
clinics	O
(	O
control	O
)	O
or	O
the	B-I
usual	I-I
care	I-I
procedure	I-I
plus	O
extra	B-I
counselling	I-I
sessions	I-I
through	I-I
phone	I-I
calls	I-I
during	O
the	O
first	O
month	O
of	O
quit	O
attempt	O
(	O
intervention	O
)	O
.	O

